Hyloris has secured licensing deals with Aguettant for its Maxigesic IV combination of paracetamol and ibuprofen in a further eight European markets through partner AFT Pharmaceuticals.

Crunched credit wiped out many biotech firms in 2009, yet some emerged from the wreckage leaner and stronger. How did they do it, asks Dr Sukaina Virji-Jeganathan.

Constellation Pharmaceuticals has secured $17.2 million in a third tranche of its $32 million series A financing round, and has appointed Dr Mark Goldsmith CEO and director.

Constellation Pharmaceuticals, a US biopharmaceutical company discovering and developing drugs targeting epigenetic regulation of the human genome, has appointed Dr Mark Goldsmith chief executive officer and director. Dr Goldsmith was previously senior executive-in-residence at the healthcare venture capital firm Prospect Venture Partners. He has also served as co-founder and CEO of Cogentus Pharmaceuticals and senior vice-president of Genencor International.